We do not allow the unauthorized collection of e-mail addresses listed on our website. Persons engaging in unauthorized collection with e-mail address collection programs or other technical devices will be subject to criminal prosecution in accordance with the Act on Information & Communications Network Utilization and Information Protection.
RNAi platform development
Lead compound discovery
Pharmacological research on OliX RNAi compounds for respiratory and neurological diseases
Pharmacological research on OliX RNAi compounds for ocular diseases
Testing efficacy of oligonucleotide therapeutics using animal models
Develop analytical methods for therapeutic candidates to determine purity and stability in support of nonclinical and clinical studies
Develop bioanalytical methods to quantitate therapeutic candidates in biological matrices for pharmacokinetic and toxicokinetic (PK/TK) studies
Manage manufacturing, analytics and quality of therapeutic candidates
Conduct safety evaluation and toxicokinetic assessment of therapeutic candidates through nonclinical studies
Establish clinical development plans for therapeutic candidates and conduct clinical studies
Business Management
Purchasing
General Affairs
Facility Management
Contingency Planning
Budget/Performance Management
Mid to Long-term Business Goals/Strategy Planning
Make official announcements about business contents, financial condition, business performance etc.
Stabilize Internal Accounting Control System
IT Infrastructure Management
IT Helpdesk
HR Policy/System Establishment, Organization/Job Design
Recruitment/HR Management
Performance Management, Employee Welfare
HR Development
Prevent, respond, handle legal disputes
Provide risk management and compliance support
Develop IP strategies for core technologies
Verify pharmaceutical R&D processes and results
Ensure product to meet the established quality standards
Develop/Maintain Client Relationships
Execute Licensing Agreements
New Business/Strategy Planning
Provide investment information in a timely manner to increase company value
Promote management activities and establish internal/external communication strategies
Create positive corporate culture through various in-house activities and employee education
Nov.
[OLX703A] Selected as national project
Receives Innovative Pharmaceutical company award
Oct.
[GalNAc platform] License and Collaboration Agreement
with Hansoh Pharma (Greater China)
Aug.
[OLX104C] Patent registered in the US
Jun.
Certified as Excellent Corporation R&D Center
Selected as KOSDAQ Rising Star
Feb.
Receives KNDA (Korea New Drug Award)
Jan.
Establishes subsidiary, mCureX Therapeutics, Inc.
Dec.
Certified as Family–friendly and Innovative pharmaceutical company
Oct.
[OLX301A · OLX301D] Expanded Out-Licensing Agreement
with Théa (Worldwide excl. Asia- Pacific)
[OLX101A] IND Phase 2 study permitted (US)
Jun.
R&D(GalNAc-siRNA) Supply contract with
global pharmaceutical company
Mar.
The GalNAc Technology from AM Chemicals is instituted
Nov.
[OLX101A] Phase 1 clinical trial for OLX10010
(candidate substance for the treatment
of hypertrophic scarring) is completed in the UK
Apr.
[OLX201A] Candidate substance for the treatment
of Idiopathic Pulmonary Fibrosis is patented in the US
Mar.
[OLX301A] Out-Licensing Agreement with Théa Open Innovation
(EU, MEA, Africa)
Feb.
[OLX103] Candidate substance for the treatment
of Atopic Dermatitis is patented in the US
OliX San Diego R&D Lab is established
Nov.
Compound for increasing siRNA and RNA interference
effects is patented in Korea
[OLX101A] Candidate substance for the treatment
of hypertrophic scarring is patented in Europe
[OLX101A] Phase 2 clinical trial is approved in Korea
for candidate substance for the treatment of hypertrophic scarring
Oct.
Phase 1 study of OLX10010, a potential treatment
for hypertrophic scar using a self-delivering RNAi compound,
is selected as a KOREA Drug Development
Fund project OliX US Inc. is established
Jul.
[OLX301A] Candidate substance for the treatment
for age-related macular degeneration is patented in the US
OliX gets listed on the KOSDAQ
May.
[OLX101A] CTA approves phase 1 clinical trial
for the treatment of hypertrophic scarring
in the UK (MHRtrial for OLX10010 (candidate A)
[OLX101A] Phase 1 clinical trial
for OLX10010 (candidate substance for the treatment of
hypertrophic scarring) is completed in Korea
Oct.
OliX passes the technology evaluation (A, A) for IPO
Jun.
The Sr. VP receives the KFDA Award
May.
Asymmetric lasiRNA platform is patented in the US
Feb.
The Nucleic Acid Eye Center is opened
Jan.
OliX moves its company to Suwon
[OLX101A] Phase 1 clinical trial is approved
in Korea forcandidate substance for
the treatment of hypertrophic scarring
Dec.
The CEO receives the Minister of Health & Welfare Award
Jul.
[OLX101A] Hypertrophic scarring therapeutics data
in Journal of Investigative Dermatology is published
Apr.
Series B funding is completed
Mar.
[OLX102] (a skin whitening substance) gets listed on ICID
Jul.
OliX gets certified as Technology Innovative Small
to Medium Enterprise (INNO-BIZ)
Jun.
Hugel Inc. makes a strategic investment in OliX
Apr.
'Development of RNA interference based atopic dermatitis
treatment' is selected as a Technology Development Support Project
(KOREA Small and Medium Business Administration)
Nov.
'Pre-clinical and clinical study of anti-scarring therapeutics BMT101
self-delivering RNAi molecule.' is selected
as a KOREA Drug Development Fund project
Oct.
The company name is changed to OliX, Inc.
Sep.
'Therapeutics development for Idiopathic Pulmonary
Fibrosis using BMT101 a pre-validated oligonucleotide drug
inhibiting fibrosis' is selected as a Korea-Singapore
R&D project (Ministry of Health and Welfare)
Aug.
Series A funding is completed
Nov.
[OLX101A] OliX makes a Collaboration and License
Agreement with Hugel Inc. for the treatment of hypertrophic scarring
May.
A patent application for cp-asiRNA platform is filed
Feb.
Angel investment is raised
Nov.
OliX moves to Gasan Digital Complex
May.
Patent application for cp-asiRNA platform is filed
Dec.
cp-asiRNA platform development is initiated
Oct.
Company affiliated research center is certified
Jun.
An exclusive license for asymmetric lasiRNA is obtained
Sep.
OliX gets certified as a venture company (Kibo Technology Fund)
Mar.
An exclusive license for asymmetric siRNA is obtained
Feb.
BMT, Inc. is established
2010.02 ~ 2012.10
2012.11 ~ 2014.09
2014.10 ~ Present